Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12antagonist bothin-vitroandex-vivoin human volunteers

The Prostaglandin E 2 Receptor EP4 Is Expressed by Human Platelets and Potently Inhibits Platelet Aggregation and Thrombus Formation

(2010) Sonia Philipose et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The role of prostanoid receptors in mediating the effects of PGE2on human platelet function

(2010) David Iyú et al.   PLATELETS

The EP3-agonist sulprostone, but not prosta glandin E2 potentiates platelet aggregation in human blood

(2010) Lisa Schober et al.   THROMBOSIS AND HAEMOSTASIS

Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation

(2010) Koh-ichi Yuhki et al.   THROMBOSIS AND HAEMOSTASIS

Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function

(2010) Robert Buckland et al.   THROMBOSIS AND HAEMOSTASIS

PGE2 decreases reactivity of human platelets by activating EP2 and EP4

(2010) James P. Smith et al.   THROMBOSIS RESEARCH

Antagonists of the EP3Receptor for Prostaglandin E2Are Novel Antiplatelet Agents That Do Not Prolong Bleeding

(2009) Jasbir Singh et al.   ACS Chemical Biology

Limitations of current therapies to prevent thrombosis: a need for novel strategies

(2009) Jean-Etienne Fabre et al.   Molecular BioSystems

Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin

(2009) S. C. Fox et al.   PLATELETS

The reversible P2Y12antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

(2008) N. L. DOVLATOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease

(2008) Stan Heptinstall et al.   PLATELETS